Effect of Dienogest therapy on the size of the endometrioma

Abstract

Studies have been published on the efficacy of Dienogest in the management of pain symptoms in endometriosis. Nonetheless, few data are available on the reducing effect on endometrioma’s size. The aim of the study was to evaluate if Dienogest could determine significant changes in size, as well as in symptoms. In this prospective observational study, patients were enrolled with pain symptoms and at least one endometrioma diagnosed via TV-US. The volume of the endometrioma and pain symptoms was measured according to the LxDxWx0.5233 formula and VAS, respectively. Dienogest 2 mg was administered daily. Follow-up visits were scheduled after 6 and 12 months of treatment to assess changes in patients' symptoms and endometrioma’s volume. Seventy patients were enrolled, 63 patients completed a 6-month treatment. The reduction of the mean volume after 6 months was 66.71%. Fifty-eight patients completed the 12 month-treatment. The reduction of the mean volume after 12 months was 76.19%. Dysmenorrhea showed a 74.05% reduction after 6 months and a 96.55% reduction after 12 months. Patients reported a reduction in dyspareunia and chronic pelvic pain of 42.71% and 48.91% after 6 months and 51.93% and 59.96% after 12 months, respectively. Dienogest leads to a statistically significant reduction of endometrioma’s volume and pain symptoms.

摘要

关于地诺孕素对子宫内膜异位症疼痛症状疗效的研究已经发表。尽管如此, 关于缩小子宫腺肌瘤体积的数据却很少。本研究旨在评估地诺孕素能否显著改变体积和症状。本项前瞻性观察性研究中, 纳入有疼痛症状并通过TV-US诊断至少有一个子宫腺肌瘤的患者。子宫腺肌瘤的体积和疼痛症状分别用LxDxWx0.5233公式和VAS测量。每日服用地诺孕素2 mg。治疗6个月和12个月后进行随访评估患者症状和子宫腺肌瘤的体积变化。纳入70名患者, 63名患者完成了6个月的治疗。6个月后体积平均缩小了66.71%。58名患者完成了12个月的治疗。12个月体积平均缩小了76.19%。6个月后痛经缓解了74.05%, 12个月后痛经缓解了96.55%。性交困难和慢性盆腔疼痛6个月后分别缓解了42.71%和48.91%, 12个月后分别缓解了51.93%和59.96%。地诺孕素使得子宫腺肌瘤体积和疼痛症状在统计学上显著减小。

The Chinese abstracts are translated by Prof. Dr. Xiangyan Ruan and her team: Beijing Obstetrics and Gynecology Hospital, Capital Medical University, Beijing 100026, China.

Keywords:

• Endometrioma
• medical therapy
• Dienogest
• size

Disclosure statement

The authors declare that they have no conflicts of interest and nothing to disclose.